APPENDIX 26: RELAPSE PREVENTIONS (ADULTS) - FOREST PLOTS

6.6.7 CONTINUED PHARMACOTHERAPY FOR RELAPSE PREVENTION

SSRIs - Number of participants who had not relapsed

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.2.1 Paroxetine						
Kumar 1999	8	27	5	28	18.2%	1.66 [0.62, 4.44]
Stein 2002b	39	151	91	148	37.7%	0.42 [0.31, 0.57]
Subtotal (95% CI)		**178**		**176**	**55.9%**	**0.77 [0.20, 2.93]**
Total events	47		96			
Heterogeneity: Tau² = 0.81; Chi² = 6.88, df = 1 (P = 0.009); I² = 85%						
Test for overall effect: Z = 0.39 (P = 0.70)						
6.2.2 Escitalopram						
Montgomery 2005	37	165	85	166	37.1%	0.44 [0.32, 0.60]
Subtotal (95% CI)		**165**		**166**	**37.1%**	**0.44 [0.32, 0.60]**
Total events	37		85			
Heterogeneity: Not applicable						
Test for overall effect: Z = 5.05 (P < 0.00001)						
6.2.3 Sertraline						
Van-Ameringen 2001	1	22	9	10	7.0%	0.05 [0.01, 0.35]
Subtotal (95% CI)		**22**		**10**	**7.0%**	**0.05 [0.01, 0.35]**
Total events	1		9			
Heterogeneity: Not applicable						
Test for overall effect: Z = 3.04 (P = 0.002)						
Total (95% CI)		**365**		**352**	**100.0%**	**0.47 [0.27, 0.82]**
Total events	85		190			
Heterogeneity: Tau² = 0.19; Chi² = 11.96, df = 3 (P = 0.008); I² = 75%						
Test for overall effect: Z = 2.64 (P = 0.008)						
Test for subgroup differences: Chi² = 5.48, df = 2 (P = 0.06), I² = 63.5%						



SSRIs - Number of participants reporting any adverse event

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.3.1 Paroxetine						
Kumar 1999	22	27	23	28	29.9%	0.99 [0.77, 1.27]
Stein 2002b	81	162	92	161	44.6%	0.88 [0.71, 1.07]
Subtotal (95% CI)		**189**		**189**	**74.5%**	**0.92 [0.79, 1.08]**
Total events	103		115			
Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 1 (P = 0.41); I² = 0%						
Test for overall effect: Z = 1.03 (P = 0.30)						
6.3.2 Escitalopram						
Montgomery 2005	63	190	72	181	25.5%	0.83 [0.64, 1.09]
Subtotal (95% CI)		**190**		**181**	**25.5%**	**0.83 [0.64, 1.09]**
Total events	63		72			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.32 (P = 0.19)						
Total (95% CI)		**379**		**370**	**100.0%**	**0.90 [0.78, 1.03]**
Total events	166		187			
Heterogeneity: Tau² = 0.00; Chi² = 1.12, df = 2 (P = 0.57); I² = 0%						
Test for overall effect: Z = 1.56 (P = 0.12)						
Test for subgroup differences: Chi² = 0.38, df = 1 (P = 0.54), I² = 0%						



SSRIs - Number of participants reporting diarrhoea

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.4.1 Paroxetine						
Kumar 1999	0	27	3	28	11.5%	0.15 [0.01, 2.74]
Stein 2002b	5	162	10	161	88.5%	0.50 [0.17, 1.42]
Subtotal (95% CI)		**189**		**189**	**100.0%**	**0.43 [0.16, 1.16]**
Total events	5		13			
Heterogeneity: Tau² = 0.00; Chi² = 0.60, df = 1 (P = 0.44); I² = 0%						
Test for overall effect: Z = 1.66 (P = 0.10)						
Total (95% CI)		**189**		**189**	**100.0%**	**0.43 [0.16, 1.16]**
Total events	5		13			
Heterogeneity: Tau² = 0.00; Chi² = 0.60, df = 1 (P = 0.44); I² = 0%						
Test for overall effect: Z = 1.66 (P = 0.10)						
Test for subgroup differences: Not applicable						



SSRIs - Number of participants reporting dizziness

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.5.1 Paroxetine						
Kumar 1999	2	27	6	28	14.0%	0.35 [0.08, 1.57]
Stein 2002b	10	162	34	161	70.8%	0.29 [0.15, 0.57]
Subtotal (95% CI)		**189**		**189**	**84.8%**	**0.30 [0.16, 0.55]**
Total events	12		40			
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%						
Test for overall effect: Z = 3.85 (P = 0.0001)						
6.5.2 Escitalopram						
Montgomery 2005	2	190	18	181	15.2%	0.11 [0.02, 0.45]
Subtotal (95% CI)		**190**		**181**	**15.2%**	**0.11 [0.02, 0.45]**
Total events	2		18			
Heterogeneity: Not applicable						
Test for overall effect: Z = 3.04 (P = 0.002)						
Total (95% CI)		**379**		**370**	**100.0%**	**0.26 [0.15, 0.45]**
Total events	14		58			
Heterogeneity: Tau² = 0.00; Chi² = 1.79, df = 2 (P = 0.41); I² = 0%						
Test for overall effect: Z = 4.73 (P < 0.00001)						
Test for subgroup differences: Chi² = 1.69, df = 1 (P = 0.19), I² = 41.0%						



Number of participants reporting drowsiness

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.6.1 Paroxetine						
Kumar 1999	4	27	1	28	29.2%	4.15 [0.49, 34.79]
Stein 2002b	7	162	1	161	29.7%	6.96 [0.87, 55.90]
Subtotal (95% CI)		**189**		**189**	**58.8%**	**5.40 [1.22, 23.92]**
Total events	11		2			
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.73); I² = 0%						
Test for overall effect: Z = 2.22 (P = 0.03)						
6.6.2 Escitalopram						
Montgomery 2005	4	190	7	181	41.2%	0.54 [0.16, 1.83]
Subtotal (95% CI)		**190**		**181**	**41.2%**	**0.54 [0.16, 1.83]**
Total events	4		7			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.98 (P = 0.33)						
Total (95% CI)		**379**		**370**	**100.0%**	**2.10 [0.37, 12.01]**
Total events	15		9			
Heterogeneity: Tau² = 1.54; Chi² = 5.76, df = 2 (P = 0.06); I² = 65%						
Test for overall effect: Z = 0.83 (P = 0.41)						
Test for subgroup differences: Chi² = 5.49, df = 1 (P = 0.02), I² = 81.8%						



SSRIs - Number of participants reporting increased anxiety

	SSRI		Placebo			Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**
6.7.1 Paroxetine						
Kumar 1999	1	27	4	28	34.2%	0.26 [0.03, 2.17]
Stein 2002b	2	162	8	161	65.8%	0.25 [0.05, 1.15]
Subtotal (95% CI)		**189**		**189**	**100.0%**	**0.25 [0.07, 0.87]**
Total events	3		12			
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%						
Test for overall effect: Z = 2.17 (P = 0.03)						
Total (95% CI)		**189**		**189**	**100.0%**	**0.25 [0.07, 0.87]**
Total events	3		12			
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.97); I² = 0%						
Test for overall effect: Z = 2.17 (P = 0.03)						
Test for subgroup differences: Not applicable						



SSRIs - Number of participants reporting insomnia

	SSRI		Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**	**M-H, Random, 95% CI**
6.8.1 Paroxetine							
Kumar 1999	1	27	2	28	10.3%	0.52 [0.05, 5.39]	
Stein 2002b	7	162	12	161	68.5%	0.58 [0.23, 1.43]	
Subtotal (95% CI)		**189**		**189**	**78.8%**	**0.57 [0.25, 1.33]**	
Total events	8		14				
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%							
Test for overall effect: Z = 1.30 (P = 0.19)							
6.8.2 Escitalopram							
Montgomery 2005	2	190	5	181	21.2%	0.38 [0.07, 1.94]	
Subtotal (95% CI)		**190**		**181**	**21.2%**	**0.38 [0.07, 1.94]**	
Total events	2		5				
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.16 (P = 0.25)							
Total (95% CI)		**379**		**370**	**100.0%**	**0.52 [0.25, 1.11]**	
Total events	10		19				
Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 2 (P = 0.91); I² = 0%							
Test for overall effect: Z = 1.69 (P = 0.09)							
Test for subgroup differences: Chi² = 0.19, df = 1 (P = 0.67), I² = 0%							



SSRIs - Number of participants reporting sweating

	SSRI		Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**	**M-H, Random, 95% CI**
6.9.1 Paroxetine							
Stein 2002b	10	162	2	161	31.4%	4.97 [1.11, 22.32]	
Kumar 1999	3	27	4	28	32.6%	0.78 [0.19, 3.16]	
Subtotal (95% CI)		**189**		**189**	**64.0%**	**1.93 [0.30, 12.25]**	
Total events	13		6				
Heterogeneity: Tau² = 1.23; Chi² = 3.24, df = 1 (P = 0.07); I² = 69%							
Test for overall effect: Z = 0.70 (P = 0.49)							
6.9.2 Escitalopram							
Montgomery 2005	4	190	12	181	36.0%	0.32 [0.10, 0.97]	
Subtotal (95% CI)		**190**		**181**	**36.0%**	**0.32 [0.10, 0.97]**	
Total events	4		12				
Heterogeneity: Not applicable							
Test for overall effect: Z = 2.02 (P = 0.04)							
Total (95% CI)		**379**		**370**	**100.0%**	**1.01 [0.21, 4.89]**	
Total events	17		18				
Heterogeneity: Tau² = 1.48; Chi² = 8.42, df = 2 (P = 0.01); I² = 76%							
Test for overall effect: Z = 0.01 (P = 0.99)							
Test for subgroup differences: Chi² = 2.68, df = 1 (P = 0.10), I² = 62.7%							



SSRIs - Number of participants reporting nausea

Study or Subgroup	SSRI Events	SSRI Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
6.10.1 Escitalopram						
Montgomery 2005	2	190	5	181	100.0%	0.38 [0.07, 1.94]
Subtotal (95% CI)		**190**		**181**	**100.0%**	**0.38 [0.07, 1.94]**
Total events	2		5			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.16 (P = 0.25)						
Total (95% CI)		**190**		**181**	**100.0%**	**0.38 [0.07, 1.94]**
Total events	2		5			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.16 (P = 0.25)						
Test for subgroup differences: Not applicable						



Anticonvulsants - Number of participants who had not relapsed

Study or Subgroup	Anticonvulsant Events	Anticonvulsant Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
Greist 2011	22	35	32	40	100.0%	0.79 [0.58, 1.06]
Total (95% CI)		**35**		**40**	**100.0%**	**0.79 [0.58, 1.06]**
Total events	22		32			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.59 (P = 0.11)						



Anticonvulsants - Number of participants reporting dizziness

Study or Subgroup	Anticonvulsant Events	Anticonvulsant Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
Greist 2011	9	80	3	73	100.0%	2.74 [0.77, 9.72]
Total (95% CI)		**80**		**73**	**100.0%**	**2.74 [0.77, 9.72]**
Total events	9		3			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.56 (P = 0.12)						



Anticonvulsants - Number of participants reporting drowsiness

Study or Subgroup	Anticonvulsant Events	Anticonvulsant Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
Greist 2011	2	80	1	73	100.0%	1.82 [0.17, 19.71]
Total (95% CI)		**80**		**73**	**100.0%**	**1.82 [0.17, 19.71]**
Total events	2		1			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.50 (P = 0.62)						



Anticonvulsants - Number of participants reporting insomnia

	Anticonvulsant		Placebo			Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**
Greist 2011	20	80	21	73	100.0%	0.87 [0.51, 1.47]
Total (95% CI)		**80**		**73**	**100.0%**	**0.87 [0.51, 1.47]**
Total events	20		21			

Heterogeneity: Not applicable

Test for overall effect: Z = 0.53 (P = 0.60)



Anticonvulsants - Number of participants reporting nausea

	Anticonvulsant		Placebo			Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**
Greist 2011	9	80	7	73	100.0%	1.17 [0.46, 2.99]
Total (95% CI)		**80**		**73**	**100.0%**	**1.17 [0.46, 2.99]**
Total events	9		7			

Heterogeneity: Not applicable

Test for overall effect: Z = 0.33 (P = 0.74)



Anticonvulsants - Number of participants reporting one or more severe side effect

	Anticonvulsant		Placebo			Risk Ratio
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Random, 95% CI**
Greist 2011	5	80	9	73	100.0%	0.51 [0.18, 1.44]
Total (95% CI)		**80**		**73**	**100.0%**	**0.51 [0.18, 1.44]**
Total events	5		9			

Heterogeneity: Not applicable

Test for overall effect: Z = 1.27 (P = 0.20)